百特醫療 (BAX) 2016 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's third-quarter 2016 earnings conference call.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2016 年第三季財報電話會議。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請於此時中斷連線。

  • I would now like turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話會議交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • - VP of IR

    - VP of IR

  • Thanks, Candace. Good morning, and welcome to our third-quarter 2016 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Candace。各位早安,歡迎參加我們 2016 年第三季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's third-quarter financial results and updated outlook for 2016 before taking your questions. I would just like to remind you that during the Q&A session, please ask just one question and one follow-up, so that we can accommodate others in the queue.

    今天早上的電話會議中,我們將先討論百特第三季財務結果與 2016 年最新展望,之後再回答各位提問。我也想提醒各位,在問答環節中,請每位提問者只問一個問題並追加一個追問,以便我們能讓隊列中的其他人也有機會發問。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development and regulatory matters, contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    接下來,我先以預先準備的發言開場,提醒各位:本簡報(包括關於我們財務展望、新產品開發與法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以了解可能導致實際結果與預期出現重大差異的因素之更多細節。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website. Now I'd like to turn the call over to Joe. Joe?

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已包含於我們今早發布並可於官網取得的財報新聞稿中。現在我想把電話交給 Joe。Joe?

  • - Chairman & CEO

    - Chairman & CEO

  • Good morning, everyone, and thanks for joining the call today. I will begin this morning by sharing some comments on our performance and progress. Then I will turn it over to Jay, who will take a closer look at the financials and provide an update on our outlook for the remainder of the year. After that, we will open up for Q&A.

    各位早安,感謝今天加入電話會議。我今天早上將先分享一些關於我們表現與進展的評論,接著交給 Jay,他會更深入檢視財務數據,並更新我們對今年剩餘期間的展望。之後我們將開放問答。

  • We are pleased with our performance in the third quarter. We continued to see momentum building across the organization as we implement the strategies outlined at our investor conference to enhance financial performance through reshaping our portfolio, transforming our cost structure and effectively deploying capital.

    我們對第三季的表現感到滿意。隨著我們落實在投資人會議上所提出的策略——透過重塑產品組合、轉型成本結構以及有效配置資本來提升財務表現——我們持續看到整個組織的動能正在累積。

  • As you saw in our press release, Baxter delivered third-quarter sales growth of 4% on a constant currency basis, and 3% on a reported basis. These results were driven by continued strong performance of fluid systems in the US and peritoneal dialysis and acute renal therapies globally. Adjusting Baxter's results were the impact of cyclophosphamides and last year's $20 million order of Protopam.

    如各位在新聞稿中所見,百特第三季在固定匯率基礎下銷售成長 4%,以報告基礎計算成長 3%。這些結果主要由美國輸液系統(fluid systems)的持續強勁表現,以及全球腹膜透析與急性腎臟治療的表現所帶動。對百特結果造成調整影響的因素包括 cyclophosphamides,以及去年 2,000 萬美元的 Protopam 訂單。

  • Sales in the quarter increased 6% globally. On the bottom line, Baxter delivered adjusted earnings of $0.56 per diluted share. These reflect the benefit of solid sales growth, along with our ongoing focus on expense management and operational excellence.

    本季全球銷售成長 6%。在獲利方面,百特每股稀釋後調整後盈餘為 0.56 美元。這反映了穩健的銷售成長所帶來的效益,以及我們持續聚焦費用管理與營運卓越。

  • Now I will take you through the performance of our businesses and franchises, where I will address sales growth on a constant currency basis to provide a clear picture of underlying operational performance. Global sales for Hospital Products totaled $1.6 billion, increasing 3%. Excluding cyclophosphamide and Protopam, Hospital Products sales advanced 7% globally, reflecting 13% growth in the US and 1% growth internationally.

    接下來我將帶各位檢視各業務與產品線的表現;為了更清楚呈現基礎營運表現,我將以固定匯率基礎說明銷售成長。醫院產品(Hospital Products)全球銷售合計 16 億美元,成長 3%。若排除 cyclophosphamide 與 Protopam,醫院產品全球銷售成長 7%,其中美國成長 13%,國際市場成長 1%。

  • Now to break out Hospital Products at a franchise level, sales in Fluid Systems totaled $576 million, up 11%. These results reflect continued strength in the US, driven by favorable demand and pricing for IV solutions, along with the strong growth in [extra steps] resulting from the ongoing successful launch of Sigma Spectrum. Note that this quarter, we anniversaried the launch of Sigma Spectrum, which is continuing to drive solid performance and increased market share.

    再以產品線層級拆分醫院產品:輸液系統(Fluid Systems)銷售為 5.76 億美元,成長 11%。這些結果反映美國市場持續強勁,主要受 IV 溶液需求與定價有利所帶動,並且 [extra steps] 也因 Sigma Spectrum 持續成功上市而呈現強勁成長。請注意,本季我們已滿 Sigma Spectrum 上市一週年;該產品持續帶動穩健表現並提升市占率。

  • Next, Integrated Pharmacy Solutions, or IPS. Sales were $563 million, decreasing 4%. Excluding cyclophosphamide and Protopam, sales increased 6%. Growth in the quarter was driven by US nutrition, which benefited from the strong sales of vitamins and amino acids, as well as our recently launched premixed generic injectables, cefazolin and vancomycin saline.

    接著是整合藥事解決方案(Integrated Pharmacy Solutions,IPS)。銷售為 5.63 億美元,下降 4%。若排除 cyclophosphamide 與 Protopam,銷售成長 6%。本季成長主要由美國營養產品帶動,受惠於維生素與胺基酸的強勁銷售,以及我們近期推出的預混通用注射劑 cefazolin 與 vancomycin saline。

  • In addition, this quarter we launched Numeta G13E in Europe. These expand our Numeta pediatric line and were the only ready-to-use triple-chamber IV nutrition product for pre-term infants. Numeta utilizes Baxter's proprietary olive oil-based lipid, which has been shown to be immuno-neutral, thereby reducing the risk of inflammation for the patient. Baxter is the only manufacturer to utilize olive oil-based lipids as part of our multi-chamber nutritional product offering.

    此外,本季我們在歐洲推出 Numeta G13E。這些產品擴充了我們的 Numeta 兒科產品線,且是唯一可即用的三腔室 IV 營養產品,適用於早產嬰兒。Numeta 採用百特專有的橄欖油基脂質,已證實具免疫中性(immuno-neutral)特性,因而可降低病患發炎風險。百特是唯一在多腔室營養產品組合中採用橄欖油基脂質的製造商。

  • Moving to Surgical Care, which includes our anesthesia and biosurgery products, third-quarter sales totaled $320 million. Global growth in the quarter was flat for the prior year, with mid single-digit growth in biosurgery offset by lower sales of anesthesia products. Anesthesia was impacted by the timing of certain government austerity measures in Europe, and the timing of certain shipments internationally. Our industry-leading inhaled anesthetics portfolio continues to represent a solid platform for future growth and global expansion.

    接著看外科照護(Surgical Care),包含我們的麻醉與生物外科產品,第三季銷售合計 3.20 億美元。本季全球成長與去年同期持平;生物外科呈現中個位數成長,但被麻醉產品銷售下滑所抵銷。麻醉產品受到歐洲部分政府緊縮措施實施時點,以及部分國際出貨時點的影響。我們業界領先的吸入式麻醉劑產品組合,仍是未來成長與全球擴張的穩固平台。

  • Finally, in Hospital Products, BioPharma Solutions, our contract manufacturing business, generated sales of $122 million, an increase of 15%. This growth reflects the benefit of an easier comp for the prior year, along with increased customer demand for products produced in our cytotoxic manufacturing facility in Germany.

    最後,在醫院產品中,生物製藥解決方案(BioPharma Solutions)——我們的委託製造業務——創造 1.22 億美元銷售,成長 15%。此成長反映去年同期比較基期較容易,以及客戶對我們德國細胞毒性(cytotoxic)製造設施所生產產品的需求增加。

  • Turning next to our Renal business, Renal sales were $977 million globally, up 6%. This reflects ongoing momentum in peritoneal dialysis, or PD, which delivered double-digit growth in the US and high single-digit growth internationally. PD growth is being driven by an expanding patient base, favorable pricing in the US and the ongoing launches of our new APD cycler, Amia, in the US, and HomeChoice Claria outside the US.

    接著看腎臟(Renal)業務:腎臟業務全球銷售為 9.77 億美元,成長 6%。這反映腹膜透析(peritoneal dialysis,PD)持續的動能;PD 在美國達到雙位數成長,在國際市場則為高個位數成長。PD 成長由病患基礎擴大、美國有利的定價,以及我們新款 APD 透析機 Amia 在美國的持續上市,以及美國以外市場 HomeChoice Claria 的上市所帶動。

  • These systems feature our innovative share source technology, which was also recently improved in Japan. Share source will be a binding feature for our new [Taguya] APD cycler in Japan, which we expect to gain local market approval shortly.

    這些系統具備我們創新的 share source 技術,而該技術近期也在日本完成改良。Share source 將成為我們在日本的新款 [Taguya] APD 透析機的關鍵功能;我們預期不久將取得當地市場核准。

  • Additionally, Q3 results reflect the positive impact of our Acute Renal business, which delivered double-digit growth globally. This reflects growing global demand for continuous renal replacement therapy, or CRRT, which we are well-positioned to address with our market-leading Prismaflex platform. Acute care is a fast-growing market where we have a substantial opportunity to serve patients and clinicians with high-value products. So this will remain a growing area of emphasis as we look ahead.

    此外,第三季結果也反映我們急性腎臟(Acute Renal)業務的正面影響,該業務在全球實現雙位數成長。這反映全球對連續性腎臟替代療法(continuous renal replacement therapy,CRRT)的需求增加;我們憑藉市場領先的 Prismaflex 平台,具備良好條件因應此需求。急性照護是一個快速成長的市場,我們有相當大的機會以高價值產品服務病患與臨床人員。因此,展望未來,這仍將是我們持續加強投入的重點領域。

  • Growth in Renal was somewhat offset by performance in in-center hemodialysis. We're taking a deliberate approach to improving profitability in our HD business. As you may have seen in our press release yesterday, we launched our novel and proprietary HDx therapy, enabled by our differentiated Theranova dialyzer. HDx therapy with Theranova has the potential to improve outcomes and raise the standard of treatment for end-stage renal disease patients. It has just launched in France, Australia and New Zealand, and will launch in several other Western European markets before the end of the year.

    腎臟業務的成長部分被院內血液透析(in-center hemodialysis)的表現所抵銷。我們正以審慎方式提升 HD 業務的獲利能力。如各位可能在昨日新聞稿中所見,我們推出全新且專有的 HDx 治療,並由我們具差異化的 Theranova 透析器所支援。搭配 Theranova 的 HDx 治療有潛力改善療效並提升末期腎臟病患者的治療標準。該產品已在法國、澳洲與紐西蘭上市,並將於年底前在其他數個西歐市場推出。

  • That's a brief snapshot of our Q3 results. I would like to close my comments by putting our quarterly performance in a broader and strategic context. At our investor conference in May, we identified three critical drivers that would elevate our performance to top-quartile levels: portfolio and innovation management, operational excellence, capital allocation. The results you have seen here today reflect the progress we have made across these three levers.

    以上是我們第三季結果的簡要概覽。我想在結語中,將本季表現放在更宏觀且具策略性的脈絡下說明。在 5 月的投資人會議上,我們確認了三項關鍵驅動因素,可將我們的表現提升至同業前四分位水準:產品組合與創新管理、營運卓越、資本配置。各位今天所看到的結果,反映我們在這三個槓桿上所取得的進展。

  • In portfolio and innovation management, we have selectively exited products from certain global markets when our presence and potential are no longer aligned with our go-forward strategy, while ensuring these markets continue to have alternate care options available for the patients.

    在產品組合與創新管理方面,當我們在某些全球市場的布局與潛力不再符合未來策略時,我們已選擇性退出部分產品,同時確保這些市場仍有其他照護選項可供病患使用。

  • We have also continued our candid assessment of legacy R&D, discontinued several programs either in non-core areas or where our prospect did not merit projected resources and demands. Choices like these are enabling us to refocus our investment on high-potential, high-value R&D, and on more strategic sales and marketing opportunities in biosurgery, PD, nutrition, premixed injectables and more.

    我們也持續對既有的研發(R&D)進行坦誠評估,並已在若干非核心領域或前景不足以支撐預期資源投入與需求的專案上,停止了數個計畫。這類決策使我們得以重新聚焦投資於高潛力、高價值的研發,以及在生物外科(biosurgery)、PD、營養、預混注射劑(premixed injectables)等領域更具策略性的銷售與行銷機會。

  • The third quarter was also a pivotal quarter in our cross-transformation efforts. In recent months, we've executed plans to rationalize our manufacturing footprint, including the closure or sale of a number of facilities in North America, Europe and Asia Pacific. These actions, where we streamline and simplify our operations, and better-position us to manage costs, while continuing to address patient and customer needs across the globe.

    第三季同樣是我們跨轉型(cross-transformation)工作中的關鍵季度。近幾個月來,我們已執行計畫以合理化我們的製造版圖(manufacturing footprint),包括關閉或出售北美、歐洲與亞太地區的多處設施。這些行動透過精簡並簡化營運,使我們更有利於成本管理,同時持續滿足全球病患與客戶的需求。

  • Earlier this month, we began a wave of organizational restructuring in our global commercial operations and certain other functions, which was the outcome of a rigorous zero-based organizational assessment. This streamline is expected to generate a higher-performing organization, along with cost savings that we contemplated in our main investor conference. Efforts like this support a leaner cost base and, again, the opportunity to channel investment in new ways.

    本月稍早,我們在全球商業營運以及其他部分職能啟動了一波組織重整,這是嚴謹的零基礎組織評估(zero-based organizational assessment)的結果。此一精簡預期將打造更高績效的組織,並帶來我們在主要投資人會議中所提及的成本節省。此類努力有助於建立更精實的成本基礎,並再次創造以新方式導引投資的機會。

  • Innovation is, of course, the most crucial ingredient in our ongoing success. And you will continue to see capital allocation choices that reinvest in the business to bolster R&D, as well as ongoing sustainable top-line growth and margin expansion. And as you have heard me say repeatedly, we continue to evaluate business development opportunities in our core growth areas and high-potential adjacencies. Any lack of news in this front should be interpreted as a sign of our discipline in assessing the [deos] strategic fit and financial merit.

    創新當然是我們持續成功最關鍵的要素。各位將持續看到我們在資本配置上的選擇:再投資於業務以強化研發,同時推動可持續的營收成長與利潤率擴張。正如各位多次聽我說過的,我們持續評估在核心成長領域與高潛力相鄰領域(adjacencies)的業務發展機會。若在此方面缺乏消息,應解讀為我們在評估該等 [deos] 策略契合度與財務效益時所展現的紀律。

  • So in sum, our success this quarter represents significant progress on our strategic journey. And while we are pleased, we are not satisfied. We will continue to make progress on our journey to transform Baxter into a top-quartile Company. And with that, I will turn over to Jay, who will walk you through the financials. Then we will open it up for your questions.

    總而言之,我們本季的成功代表我們在策略旅程上取得重大進展。雖然我們感到欣慰,但並不滿足。我們將持續推進轉型之路,將 Baxter 打造成同業前四分位(top-quartile)的公司。接下來我將交給 Jay,由他帶各位檢視財務表現,之後我們將開放提問。

  • - CFO

    - CFO

  • Thanks, Joe, and good morning, everyone. As Joe mentioned, we are pleased with our third-quarter results, demonstrating continued progress towards achieving our long-term financial goals. Operationally, sales increased 4% in the quarter, and on a reported basis, sales grew 3%. Growth came in at the high end of our expectations, driven primarily by favorability in PD and Nutrition Therapies.

    謝謝你,Joe,各位早安。正如 Joe 所提到的,我們對第三季的結果感到滿意,顯示我們持續朝長期財務目標邁進。以營運面來看,本季銷售成長 4%,以報表口徑(reported basis)則成長 3%。成長落在我們預期區間的高端,主要由 PD 與營養治療(Nutrition Therapies)的有利表現所帶動。

  • Walking through the rest of the P&L, adjusted gross margin of 44.9% represents an improvement of more than 100 basis points over the prior-year, driven by a positive sales mix, improved pricing in select areas of the portfolio, and favorable manufacturing performance in the quarter. Adjusted SG&A totaled $611 million and decreased 9% on a reported basis. The primary driver of the improvement was our ongoing focus on controlling expenses and the benefit from lower pension expense.

    接著說明損益表(P&L)的其餘部分:調整後毛利率為 44.9%,較去年同期提升超過 100 個基點,主要受惠於正向的銷售組合、產品組合中部分領域的定價改善,以及本季製造表現良好。調整後銷售、一般及行政費用(SG&A)合計 6.11 億美元,以報表口徑下降 9%。改善的主要驅動因素是我們持續聚焦費用控管,以及退休金費用下降所帶來的效益。

  • TSA income totaled approximately $25 million in the quarter, compared to approximately $30 million in the third quarter of 2015. TSA income from Shire will continue to decline as the need for these services ramps down, which is expected to be by mid-2017.

    本季 TSA 收入合計約 2,500 萬美元,相較於 2015 年第三季約 3,000 萬美元。來自 Shire 的 TSA 收入將隨著對這些服務的需求逐步降低而持續下滑,預期至 2017 年年中。

  • During the third quarter, we did report a charge of approximately $130 million for restructuring activities, of which approximately $100 million was related to employee termination costs, which are expected to generate over $100 million of annual savings once fully implemented. As Joe mentioned, these actions were initiated earlier this month and were contemplated in the long-term financial guidance we provided in May. We will continue to optimize our cost structure as we move forward.

    第三季我們認列了約 1.30 億美元的重整(restructuring)相關費用,其中約 1.00 億美元與員工終止聘用成本相關;在全面落實後,預期每年可產生超過 1.00 億美元的節省。如 Joe 所提到,這些行動於本月稍早啟動,且已納入我們在 5 月提供的長期財務指引中。我們將在未來持續優化成本結構。

  • Adjusted R&D spending in the quarter of $129 million decreased 8% versus the prior year. While we did benefit in the quarter from the discontinuation of select programs, we expect to begin redeploying that spend in areas like biosurgery and premixed injectables, beginning in the fourth quarter.

    本季調整後研發(R&D)支出為 1.29 億美元,較去年下降 8%。雖然本季受惠於停止部分專案,但我們預期自第四季起,將開始把這些支出重新配置至如生物外科(biosurgery)與預混注射劑(premixed injectables)等領域。

  • Adjusted operating margin in the quarter was 16% and compared favorably to our expectations, driven by positive product mix, lower R&D spend, and the benefit of our initiatives to control spending and reduce expenses. This represents a 480-basis point improvement over the third quarter of 2015.

    本季調整後營業利益率為 16%,優於我們的預期,主要受惠於正向的產品組合、較低的研發支出,以及我們控管支出與降低費用的各項措施所帶來的效益。相較 2015 年第三季,這代表提升 480 個基點。

  • Interest expense was $14 million in the quarter. During the quarter, we took advantage of favorable market conditions and executed a $1.6 billion three-tranche debt offering consisting of 5-, 10-, and 30-year notes. Proceeds from this offering were used to retire a series of existing bonds maturing in the near- to intermediate-term, as well as pay off all of our outstanding commercial paper. As a result of this transaction, Baxter's bond maturity profile increased from an average of nine years to 15 years, and our average coupon rate declined by nearly 1%.

    本季利息費用為 1,400 萬美元。本季我們把握有利的市場條件,完成 16 億美元、三個期別的債務發行,包含 5 年期、10 年期與 30 年期票據。本次發行所得用於償還一系列即將於短期至中期到期的既有債券,並清償我們所有未償還的商業本票(commercial paper)。因此,Baxter 的債券到期結構(bond maturity profile)平均年期由 9 年延長至 15 年,平均票面利率(coupon rate)也下降近 1%。

  • Adjusted other income totaled $4 million in the quarter, primarily resulting from a foreign exchange gain on a balance sheet position. The adjusted tax rate was 22% for the quarter, slightly higher than expectations, driven by earnings mix. And as previously mentioned, adjusted earnings of $0.56 per diluted share exceeded our guidance of $0.43 to $0.45 per share.

    本季調整後其他收益合計 400 萬美元,主要來自資產負債表部位的外匯收益。調整後有效稅率為 22%,略高於預期,主要受獲利組合影響。如先前所述,調整後每股稀釋盈餘(EPS)0.56 美元,高於我們每股 0.43 至 0.45 美元的指引。

  • Relative to the midpoint of our range, this favorability was driven by approximately $0.11 of operational strength, and a $0.02 benefit from interest and other income. This was partially offset by approximately $0.01 due to a higher share count and tax rate.

    相較於我們區間中點,這項有利差異主要來自約 0.11 美元的營運動能,以及利息與其他收益帶來的 0.02 美元效益;部分被約 0.01 美元所抵銷,原因是流通股數增加與稅率較高。

  • Along with our equity-for-equity exchange which we executed in the latter part of the second quarter, during the third quarter, we opportunistically repurchased $40 million or approximately one million shares, during the quarter. These repurchases were more than offset by higher-than-expected option-related dilution, given Baxter's stock performance during the quarter.

    除我們在第二季後段完成的以股換股(equity-for-equity)交換外,第三季我們也把握時機回購 4,000 萬美元、約 100 萬股的股票。由於本季 Baxter 股價表現帶來高於預期的選擇權相關稀釋(option-related dilution),上述回購的效果被其抵銷。

  • Let me conclude my comments this morning by providing an update on our outlook for 2016. Starting with sales, on a constant currency basis, we now expect 2016 full-year sales for Baxter to increase approximately 4%. And after adjusting for the US cyclophosphamide impact, we expect underlying operational growth of approximately 5%. On a reported basis, including the impact of foreign exchange, we expect sales to increase approximately 2%.

    最後,我在今天早上的發言將以更新我們對 2016 年展望作結。先從銷售來看,以固定匯率(constant currency)計算,我們目前預期 Baxter 2016 年全年銷售將成長約 4%。若調整美國 cyclophosphamide 的影響,我們預期基礎營運成長約 5%。以報表口徑(reported basis)計算並納入外匯影響,我們預期銷售將成長約 2%。

  • We expect growth in the Hospital Products business of 3% to 4%, or approximately 5% excluding US cyclophosphamide. Within the Hospital Products franchises, we expect sales growth of low double-digits for fluid systems, driven by continued strength in the US business.

    我們預期醫院產品(Hospital Products)業務成長 3% 至 4%,若排除美國 cyclophosphamide 則約為 5%。在醫院產品各事業群中,我們預期輸液系統(fluid systems)銷售將呈低雙位數成長,主要由美國業務持續強勁所帶動。

  • For the Integrated Pharmacy Solutions franchise, we expect sales to decline versus the prior year, including the impact of US cyclophosphamide. We've adjusted our full-year sales forecast for cyclo, and now expect full-year sales of $210 million, with the assumption that no additional competitors enter the market during the fourth quarter of 2016. After adjusting for cyclophosphamide, sales are expected to increase 2% to 3% in IPS, or 4% to 5% excluding the impact of both cyclo and Protopam.

    就整合藥局解決方案(Integrated Pharmacy Solutions, IPS)事業群而言,我們預期銷售將較去年下滑,包含美國 cyclophosphamide 的影響。我們已調整 cyclo 的全年銷售預測,現預期全年銷售為 2.10 億美元,並假設 2016 年第四季不會有其他競爭者進入市場。若調整 cyclophosphamide 影響,IPS 銷售預期成長 2% 至 3%;若同時排除 cyclo 與 Protopam 的影響,則預期成長 4% 至 5%。

  • Within the Surgical Care franchise, we anticipate sales to grow approximately 1%. And finally, for the Hospital Products business, we now expect BPS and other to increase low single-digits. For the Renal business, we now expect full-year sales to increase 4% to 5%, driven by continued growth in our PD and acute businesses, offset by lower sales in our in-center HD business.

    在外科照護(Surgical Care)事業群中,我們預期銷售成長約 1%。最後,就醫院產品(Hospital Products)業務而言,我們目前預期 BPS 及其他項目將呈低個位數成長。至於腎臟(Renal)業務,我們目前預期全年銷售成長 4% 至 5%,主要由 PD 與急性(acute)業務持續成長所帶動,但部分被院內血液透析(in-center HD)業務銷售下降所抵銷。

  • Moving down the P&L, we now expect an operating margin of approximately 13%, a 100-basis point improvement versus our previous guidance and a 200-basis point improvement relative to our original guidance. This increase is driven by improved sales and ongoing disciplined management of expenses. We expect interest expense to total approximately $70 million.

    往下看損益表(P&L),我們目前預期營業利益率約為 13%,較先前指引提升 100 個基點,亦較原始指引提升 200 個基點。此一上調主要由銷售改善與持續嚴謹的費用管理所驅動。我們預期利息費用合計約 7,000 萬美元。

  • For 2016, we expect other income of approximately $55 million, which does reflect a benefit of approximately $10 million in the fourth quarter related to the disposition of an equity investment. For the year, we now expect an average of adjusted tax rate of approximately 21%, driven by the expected mix of earnings.

    就 2016 年而言,我們預期其他收益約 5,500 萬美元,其中確實包含第四季因處分一項股權投資而帶來約 1,000 萬美元的利益。全年方面,我們目前預期調整後平均有效稅率約為 21%,主要受預期獲利組合影響。

  • For full-year 2016, we anticipate an average share count of 550 million shares. Based on these factors, we now expect 2016 adjusted earnings, excluding special items, of $1.88 to $1.91 per diluted share, as compared to our previous guidance of $1.69 to $1.74 per diluted share.

    就2016年全年而言,我們預期平均流通股數為5.5億股。基於這些因素,我們目前預期2016年調整後盈餘(不含特殊項目)為每股稀釋後1.88至1.91美元,相較於我們先前指引的每股稀釋後1.69至1.74美元。

  • Finally, for the year, we expect operating cash flow of approximately $1.45 billion, and CapEx of approximately $800 million, resulting in approximately $650 million in free cash flow. This represents an increase of 30% from our original guidance of $500 million.

    最後,就全年而言,我們預期營運現金流約為14.5億美元,資本支出(CapEx)約為8億美元,因而自由現金流約為6.5億美元。這較我們原先指引的5億美元增加約30%。

  • We're applying the same discipline to managing capital expenditures as we are to our expense base, which has resulted in a benefit of approximately $100 million in lower CapEx for the year. In addition, we have initiated programs focused on improving our days payable and days receivable ratios, which will benefit operating cash flow going forward.

    我們以管理費用基礎同樣的紀律來管理資本支出,因而使全年CapEx降低約1億美元。此外,我們已啟動聚焦於改善應付帳款天數與應收帳款天數比率的計畫,未來將有助於提升營運現金流。

  • Specific to the fourth quarter of 2016, we expect sales growth to increase approximately 2% on both a reported and constant currency basis. The growth does represent the deceleration from previous quarters, given our previously announced decision to exit select markets outside the US. The collective impact of these exits impacts the top line by approximately 1 percentage point.

    就2016年第四季而言,我們預期銷售成長在報告基礎與固定匯率基礎下皆約增加2%。鑑於我們先前已宣布決定退出美國以外的部分市場,成長確實較前幾季放緩。這些退出行動的合計影響,約使營收(top line)減少1個百分點。

  • In addition, lower cyclo sales compared to the prior year also negatively impacted the top line by approximately 1 percentage point in the quarter. Adjusting for these two factors, growth in the quarter would be approximately 4%, which is in line with our long-term projections. And we expect adjusted earnings, excluding special items, of $0.49 to $0.52 per diluted share. This guidance reflects increased investments in R&D and incremental investments in SG&A.

    此外,與去年同期相比,cyclo銷售較低也在本季對營收造成約1個百分點的負面影響。若排除這兩項因素,本季成長約為4%,與我們的長期預測一致。我們並預期調整後盈餘(不含特殊項目)為每股稀釋後0.49至0.52美元。此指引反映我們在研發(R&D)上的投資增加,以及在銷售、一般及行政費用(SG&A)上的額外投資。

  • With that, we can now open up the call for Q&A.

    接下來,我們現在可以開放問答(Q&A)。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • (Operator Instructions)

    (接線員指示)

  • Our first question comes from David Lewis of Morgan Stanley. Your line is now open.

    我們的第一個問題來自摩根士丹利(Morgan Stanley)的David Lewis。您的線路已開通。

  • - Analyst

    - Analyst

  • Good morning. Just two quick questions, one on margins and one on CapEx. So maybe just starting with margins for a second. If I think about the fourth quarter, Jay, I think your guidance of $0.49 to $0.52 kind of implies something around 14% margins. So two things. What would drive the depression sequentially? And obviously if you do 16% here in the third quarter versus your sort of 14%, 15% outlook for 2018, how are you feeling about those long-term margin targets? So fourth quarter and obviously the 2018 outlook, and then a quick follow-up.

    早安。我只有兩個簡短問題,一個關於利潤率,一個關於資本支出(CapEx)。先從利潤率談起。如果我看第四季,Jay,我認為你們0.49到0.52美元的指引大概隱含約14%的利潤率。有兩點:什麼因素會導致利潤率季比下滑?另外,若第三季做到16%,而你們對2018年的展望大概是14%、15%,你們對這些長期利潤率目標的看法如何?也就是第四季以及2018年的展望,然後我再快速追問一個問題。

  • - CFO

    - CFO

  • Great. Good morning, David. As far as the fourth quarter goes, overall, we were obviously very pleased with the margin performance in the third quarter. So the 16% represents the highest quarterly margin target that we've achieved since the spinoff.

    很好。早安,David。就第四季而言,整體來說,我們對第三季的利潤率表現顯然非常滿意。因此,16%代表我們自分拆以來所達成的最高單季利潤率水準。

  • As we move to Q4, we do expect a slight downtick in the operating margin of the business, and really there's a couple of drivers of that. One is, we are going to be accelerating some R&D investments in both biosurgery and premixed injectables, as I mentioned. So that will be one factor that increases the R&D spending relative to our current level.

    進入第四季,我們確實預期公司營業利益率會小幅下滑,主要有幾個驅動因素。第一,我們將如我所提到的,加速在生物外科(biosurgery)與預混注射劑(premixed injectables)方面的研發投資。因此,這將是使研發支出相對於目前水準增加的一項因素。

  • And then the second item relates to SG&A. We do expect a slight uptick as well in SG&A in the fourth quarter, as a percent of sales. There's a couple of factors going on there. One is, we do have historic seasonality. So if you look at Baxter over the last many years, we normally have an uptick in spending in the fourth quarter. We do expect that to repeat.

    第二項與SG&A有關。我們也預期第四季SG&A占銷售額的比重會小幅上升。這裡有幾個因素。其一,我們確實有歷史性的季節性。如果你回顧Baxter過去多年,通常第四季支出會上升。我們預期這種情況會再度出現。

  • And then the second factor that's going on with respect to SG&A is, one of the topics we discussed in our main investor conference relates to what we call local initiatives. The idea that, given the diverse geographic portfolio that we have in place, and the product portfolio, we really have a tremendous opportunity to accelerate growth by unlocking some of the entrepreneurial spirit outside the US. But frankly, that comes with it, an SG&A cost.

    另外一個與SG&A相關的因素是:我們在主要投資人會議中討論過的主題之一,與我們所稱的「在地倡議」(local initiatives)有關。其概念是,鑑於我們具備多元的地理布局與產品組合,我們其實有很大的機會,透過釋放美國以外地區的創業精神來加速成長。但坦白說,這也會伴隨SG&A成本。

  • And so over the course of the last quarter, we have approved a number of investment initiatives which we believe will benefit 2017 and 2018, but do have a slight cost associated with them. So for these reasons, we do expect a slight downtick as it relates to the overall margin, but again, feel very confident in the operational performance.

    因此在上一季期間,我們已核准多項投資倡議,我們相信將有利於2017與2018年,但也會帶來些許相關成本。基於這些原因,我們確實預期整體利潤率會小幅下滑;但再次強調,我們對營運表現仍非常有信心。

  • As we look to 2017, I think it's too early to get into forecast for 2017. What I can tell you is, in our May investor conference, we shared a series of projections for 2018 and 2020. And it is clear, the data points that we have point to accelerated performance relative to those expectations. So we have a higher level of confidence in our ability to achieve those numbers and exceed those numbers today than we did when we shared them in May of 2016.

    至於2017年,我認為現在談2017年的預測還太早。我能告訴你的是,在我們5月的投資人會議上,我們分享了一系列對2018年與2020年的預測。而很明顯地,我們目前掌握的數據顯示,表現正加速、優於那些預期。因此,相較於我們在2016年5月分享時,我們現在對達成並超越那些數字的能力更有信心。

  • - Analyst

    - Analyst

  • Okay, Jay, very helpful. And just one quick follow-up, I think, for me. You hinted this last quarter, but the cash flow numbers here, specifically CapEx guidance, was fairly remarkable. So can you help us understand what's driving an $800 million number? I think you gave us a $750 million number as the long-term target, so that is sort of materially sort of ahead of the plan. How much of that is timing? Or does 800 represent the new normal as we cycle into 2017? Thanks.

    好的,Jay,很有幫助。再快速追問一個我這邊的問題。你們上季有稍微提到,但這次的現金流數字,特別是CapEx指引,相當令人驚訝。你能幫我們理解是什麼驅動了8億美元這個數字嗎?我記得你們給的長期目標是7.5億美元,所以這等於明顯超前於計畫。這當中有多少是時點因素?或者當我們進入2017年時,8億美元是否代表新的常態?謝謝。

  • - CFO

    - CFO

  • Sure. One of the numbers I think the team is most proud of is the free cash flow performance. As I mentioned in the script, we are increasing it from $500 million to $650 million. And really there is a couple of different components to that. One is, operating cash flow, we are raising approximately $50 million, and this is an area where I believe there will be more substantial benefit from some of the programs that we've initiated this year, in future years.

    當然。我認為團隊最引以為傲的數字之一就是自由現金流表現。如同我在講稿中提到的,我們將其從5億美元上調至6.5億美元。這主要由幾個不同組成部分所驅動。其一是營運現金流,我們上調約5,000萬美元;而我相信,這個領域在未來年度,將能從我們今年啟動的一些計畫中獲得更顯著的效益。

  • So we're spending a lot of time as a team on working capital, days payable, days sales outstanding, and inventory -- how can we drive that down. And those are balances that you don't switch on overnight, but over time, with rigor and focus, you can drive a real result in these categories. So we don't really have much benefit this year, but 2017, 2018, 2019, you'll expect to see some meaningful working capital improvements.

    因此,團隊投入大量時間在營運資金上:應付帳款天數、應收帳款週轉天數(DSO)以及存貨——我們如何把這些降下來。這些不是一夕之間就能改變的餘額,但隨著時間推進,只要嚴謹並聚焦,就能在這些類別上取得實質成果。因此今年我們並沒有太多效益,但在2017、2018、2019年,你們將會看到一些有意義的營運資金改善。

  • Where we were able to drive an impact this year -- and frankly, I believe this will be sustainable -- is in CapEx. We did a couple things this year which I think provided a very real benefit. First, we did a zero-based budget for CapEx, which we review quarterly with our senior leadership team. So our top executives at the Company sit down on a quarterly basis.

    而我們今年能夠帶來影響——坦白說,我也相信這將可持續——是在CapEx方面。今年我們做了幾件事,我認為帶來非常實際的效益。第一,我們對CapEx採用零基預算(zero-based budget),並由高階領導團隊按季檢視。因此,公司最高層主管每一季都會坐下來檢討。

  • And the result of that is twofold. One, we did cancel a number of low-value-adding programs. But second, for every single program that we had, the challenge to the team was, how can we do this more cost-effectively? And the results were very impressive.

    其結果有兩個面向。第一,我們取消了多個低附加價值的專案。第二,對於我們每一個專案,我們都要求團隊思考:如何以更具成本效益的方式完成?成果非常令人印象深刻。

  • So the second piece relates to an incentive take that we put in place at the beginning of the year. For our top employees, we have a short-term incentive plan for the top several-thousand employees. And last year, there was no cash flow component to this. This year, recognizing the challenge that we face with CapEx being 9% of sales, we installed a free cash flow trigger for our short-term incentive plan. By focusing on free cash flow now, we have our entire organization geared and charging towards driving improvements in this important metric.

    第二部分與我們在年初導入的一項激勵機制有關。對於我們的核心員工——前幾千名員工——我們有一個短期激勵計畫。去年,該計畫沒有現金流的構成項目。今年,考量到我們面臨CapEx占銷售額9%的挑戰,我們在短期激勵計畫中加入了自由現金流的觸發條件(trigger)。透過現在聚焦自由現金流,我們讓整個組織都朝著改善這項重要指標而調整並全力推進。

  • So while that is harder to quantify, I believe that, that's paid a real dividend in our numbers and creativity, as we think about addressing CapEx spending. But frankly, this is one area where I believe we've achieved a new normal, and we'll continue to drive performance from here.

    因此,雖然這較難量化,但我相信這已在我們的數字表現與創意上帶來實質回報,尤其是在我們思考如何處理CapEx支出時。不過坦白說,這是我認為我們已達成「新常態」的一個領域,並且我們將在此基礎上持續推動績效提升。

  • - Chairman & CEO

    - Chairman & CEO

  • I would just like to add one component to Jay's great answer, is that this is a sustainable level of capital. So this is not a one-year conversation. We have changed how we look at capital, how we invest in different places in the world, and also our new technologies, our point-of-care, which is solution-making on-demand. And also how we service emerging markets, with on-demand manufacturing solutions for 100 to 120 patients. We have changed how, structurally, we see capital.

    我只想在 Jay 很精彩的回答上再補充一點:這是一個可持續的資本水準。所以這不是一年的討論。我們已經改變了我們看待資本的方式、我們在全球不同地區的投資方式,也包括我們的新技術——我們的即時照護(point-of-care),也就是按需製作解決方案。以及我們如何服務新興市場,透過可按需製造、可服務 100 到 120 位病患的解決方案。我們已經改變了我們在結構上如何看待資本。

  • - Analyst

    - Analyst

  • Great. Thanks, guys.

    很好。謝謝各位。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. Our next question comes from Matt Taylor of Barclays. Your line is now open.

    謝謝。下一個問題來自 Barclays 的 Matt Taylor。您的線路已開通。

  • - Analyst

    - Analyst

  • Hi, thanks for taking the question. I wanted to just touch again on the margins and talk a little bit about some of the components that are contributing to the good leverage that you saw in SG&A and gross margin. Could you just articulate what you've sort of done and seen in the plan so far? And then the initiatives that are yet to be really tapped that we could see leverage from in 2018 and beyond?

    嗨,謝謝讓我提問。我想再談一下利潤率,並稍微談談有哪些因素促成了您在銷售、一般及行政費用(SG&A)與毛利率上看到的良好槓桿效應。您能否說明一下到目前為止在計畫中做了哪些、看到了哪些成果?以及還有哪些尚未真正充分發揮、我們可能在 2018 年及之後看到槓桿效益的措施?

  • - CFO

    - CFO

  • Sure. Yes, clearly this was a fabulous quarter for our operating margin. And I would say it was -- contributing to it were gross margin, SG&A leverage and some R&D leverage. From a gross margin standpoint -- let's start with that -- there were a number of factors in play. We've talked a lot about this concept of portfolio management and business mix, and upgrading the business mix. And as we look at the Q3 results from Baxter, you start to see that story playing out.

    當然。是的,這一季我們的營業利益率表現非常出色。我會說,貢獻因素包括毛利率、SG&A 槓桿效應以及部分研發(R&D)槓桿效應。從毛利率角度——我們先從這裡開始——有多項因素同時作用。我們談了很多投資組合管理與業務組合(business mix)的概念,以及提升業務組合。當我們看 Baxter 的第三季結果時,你開始看到這個故事正在發酵。

  • So for example, we saw a very strong performance in our US hospital business in the [CET] area, and access. Our CETs in the United States grew approximately 20%. That simple business mix factor contributed to our margin. And as we increase the installed base in the United States of Sigma Spectrum, we will continue to benefit from this mix factor as it moves forward.

    例如,我們在美國醫院業務的 [CET] 領域以及通路(access)方面表現非常強勁。我們在美國的 CET 成長約 20%。這個單純的業務組合因素就對我們的利潤率有所貢獻。隨著我們在美國擴大 Sigma Spectrum 的裝機基礎(installed base),我們將持續受惠於這個業務組合因素在未來的推進。

  • From an international standpoint, you'll see that we have lower fluid system sales. But in areas like renal, in particular, where we had double-digit acute growth, and PD growth, where we have been very focused on accelerating growth, those are two good margin areas that provided uplift from a business mix standpoint.

    從國際市場來看,你會看到我們的輸液系統(fluid system)銷售較低。但在腎臟(renal)等領域,特別是我們急性(acute)業務出現兩位數成長,以及腹膜透析(PD)成長——我們一直非常專注於加速成長——這兩個都是高毛利領域,從業務組合角度帶來了提升。

  • And finally, from a business mix standpoint, you heard Joe comment earlier in this call about how we are going to manage in-center HD for profitability -- very focused on driving this. So while that business had lower sales, it had a business mix and, from our standpoint, the focus on profitability. Those are three examples from a gross margin standpoint where business mix played an impact.

    最後,從業務組合角度,你也聽到 Joe 在本次電話會議稍早提到,我們將以獲利為導向來管理院內血液透析(in-center HD)——非常專注於推動這件事。因此,雖然該業務銷售較低,但其業務組合以及我們對獲利的聚焦,對我們而言是重點。以上是三個毛利率層面、業務組合產生影響的例子。

  • The second comment related to gross margin is manufacturing and performance. Overall, we had solid manufacturing performance, we had good volumes in Q2 and Q3. The result of that is a P&L benefit from a manufacturing standpoint. We'll expect to continue driving manufacturing performance going forward. This is a real area of focus for us -- how can we effectively utilize our facilities. In Joe's prepared remarks, you heard him reference, we've closed or sold a number of facilities over the course of this year that leads to better leveraging of the network.

    第二點與毛利率相關的是製造與績效。整體而言,我們的製造表現穩健,第二季與第三季的出貨量也不錯。其結果是在製造端帶來損益表(P&L)的效益。我們預期未來會持續推動製造績效。這是我們真正的重點領域——如何有效利用我們的設施。在 Joe 的事先準備發言中,你也聽到他提到,我們在今年期間已關閉或出售多處設施,這有助於更好地槓桿化整體網路。

  • The final piece related to gross margin is this idea of -- how can we think creatively about our business arrangements, either through pricing or being thoughtful about the services that we provide? A simple example of this is, we're really focused in our US renal business on limiting the amount of overnight shipping that occurs. For us, that has historically been a real cost that we have born, and it has impacted our margin. By focusing on that, we are able to drive a better margin. So those are the three drivers that have impacted our gross margin.

    與毛利率相關的最後一塊,是這個想法——我們如何以更有創意的方式思考我們的商業安排,無論是透過定價,或是更審慎地思考我們提供的服務?一個簡單例子是:我們在美國腎臟業務上非常專注於限制隔夜運送(overnight shipping)的發生。對我們而言,這在歷史上一直是一項我們承擔的實質成本,並影響了我們的利潤率。透過聚焦這件事,我們能夠推動更好的利潤率。因此,以上三項驅動因素影響了我們的毛利率。

  • Moving to R&D, we made a couple of tough decisions over the course of this year, with respect to a project like Vivia. And so as a result of that, we saw lower R&D spending in the quarter. Now to my earlier comment, I do expect an uptick in this as we start to reinvest in some exciting new areas for us that have nearer-term payback than the Vivia project. But in the quarter, this idea of rigorous capital allocation did play out in the R&D spend.

    轉到研發方面,我們在今年做出了一些艱難的決定,涉及像 Vivia 這樣的專案。因此,我們在本季看到研發支出較低。回到我先前的評論,當我們開始在一些對我們而言更令人振奮、且比 Vivia 專案更接近短期回收的新領域再投資時,我確實預期研發支出會回升。但在本季,嚴謹的資本配置確實反映在研發支出上。

  • And then finally from the SG&A standpoint, I would make a couple comments here. First, this idea of zero-based spending, challenging every single dollar that we have in place, that's something that the Company has adopted from a process standpoint. So as we went through our budgeting process this year, we had a very rigorous zero-based spending approach and zero-based organization approach in place, applying these techniques to our cost structure.

    最後談到 SG&A,我想在這裡做幾點說明。第一,是零基預算(zero-based spending)的概念,對我們現有的每一塊錢都提出挑戰,這是公司在流程面已採納的做法。因此,在我們今年的預算編製過程中,我們採用了非常嚴謹的零基支出方法與零基組織(zero-based organization)方法,將這些技術應用於我們的成本結構。

  • But I think, beyond that, culturally, the entire organization is incredibly aware of spending and driving results. The number of ideas that we're generating from our organization at-large with respect to simplification, with respect to savings ideas, is remarkable. And that simple phenomena has played out in our SG&A numbers for the quarter.

    但我認為除此之外,在文化層面,整個組織對支出與推動成果都極其敏感。我們從整個組織所產生的點子數量——無論是簡化,或是節省成本的想法——都非常驚人。而這個現象在本季的 SG&A 數字中也反映出來。

  • - Analyst

    - Analyst

  • Thanks. Maybe just one follow-up. You've had a lot of momentum in the pumps. Can you talk a little bit about how durable that could be as you continue to kind of gain back share there? And whether that's going to create any headwind for you in 2017 as you try to grow over these strong placement numbers?

    謝謝。也許再追問一個問題。你們在幫浦(pumps)方面動能很強。你能談談當你們持續在那裡收復市占時,這種動能可能有多持久嗎?以及當你們試圖在這些強勁的裝機數字之上繼續成長時,是否會在 2017 年對你們造成任何逆風?

  • - Chairman & CEO

    - Chairman & CEO

  • We had a very good performance in Spectrum since its launch about a year ago. We gained market share, we are back to number-two position in the market, and clearly that was a very rapid penetration. We don't see the same rate of penetration going forward, but we continue to see us gaining market share in the large-volume pump market in the US.

    自大約一年前 Spectrum 上市以來,我們在 Spectrum 的表現非常好。我們提升了市占率,回到市場第二名的位置,而且顯然滲透速度非常快。未來我們不會看到同樣的滲透速度,但我們仍持續看到我們在美國大容量幫浦市場(large-volume pump market)中提升市占。

  • We also are very committed to the pump business and technology, and we will be continuing to invest resources in developing not only the portfolio for the US, but also for outside the US. But to the point of comparables, we are coming to the point we are anniversaring our pump launch. So clearly we cannot expect this business to continue to deliver growth in the 20%-plus every quarter.

    我們也非常致力於幫浦業務與技術,並將持續投入資源,不僅開發美國市場的產品組合,也包括美國以外的市場。但就可比基期而言,我們正接近幫浦上市一週年的時間點。因此,我們顯然不能期待這項業務每一季都能持續交出 20% 以上的成長。

  • - Analyst

    - Analyst

  • Great. Thanks for the comment.

    很好。謝謝你的說明。

  • Operator

    Operator

  • Thank you. Our next question comes from Vijay Kumar of Evercore. Your line is now open.

    謝謝。下一個問題來自 Evercore 的 Vijay Kumar。您的線路已開通。

  • - Analyst

    - Analyst

  • Hey, guys, congrats on a great quarter. Maybe one near-term and one medium-term question. Obviously phenomenal 3Q numbers. When you look at the fourth-quarter numbers, an organic of 2% -- that's a sequential [decelamancy]. What kind of cycle assumptions do we have? Can you just give some clarity on the top line, please?

    嘿,各位,恭喜這一季表現很棒。也許一個短期問題和一個中期問題。第三季數字顯然非常亮眼。當你們看第四季的數字時,有機成長 2%——這是環比的[decelamancy](減速)。我們對週期(cycle)有什麼假設?能否請你們就營收端(top line)提供一些更清楚的說明?

  • - CFO

    - CFO

  • Yes, overall, there's essentially two drivers of the deceleration in the fourth quarter. One is cyclo. While we're not anticipating an incremental competitor in cyclophosphamide, we do expect lower levels than prior years -- down about $20 million or roughly 1 point of growth, to $45 million in the quarter. So that's a deceleration that we've expected, and kind of consistent with how we've thought about things.

    是的,整體而言,第四季減速主要有兩個驅動因素。第一是 cyclo(環磷醯胺)。雖然我們不預期在環磷醯胺方面會出現新增競爭對手,但我們確實預期水準會低於往年——本季約下降 2,000 萬美元,或約 1 個成長點數,降至本季 4,500 萬美元。因此,這是我們已預期的減速,也與我們一貫的思考方式大致一致。

  • As we look at the other area that has impacted our Q4 results, we have always talked about this idea of rigorously going through our portfolio and ensuring that every single sale that we make is one that contributes positively to the economics of Baxter. And so in support of that, we did walk away from roughly $130 million in sales on an annual basis. Which amounts to roughly 1 point of growth impact in the quarter.

    再看另一個影響我們第四季結果的領域,我們一直談到這個概念:嚴謹地檢視我們的產品組合,並確保我們做出的每一筆銷售都能對 Baxter 的經濟效益做出正向貢獻。為了支持這點,我們確實放棄了約每年 1.3 億美元的銷售額。換算到本季,大約相當於 1 個成長點數的影響。

  • Now the good news is, this has limited to no impact on the bottom line. The sales were essentially breakeven, and we've been able to eliminate all the costs associated with those sales. So while on the bottom line, there's no impact, it does impact the top line a bit. If I were to adjust for these two factors, the 2% growth would be more like our normal, expected run rate growth of 4%.

    好消息是,這對淨利(bottom line)的影響有限甚至沒有。這些銷售基本上是損益兩平,而我們也已能夠消除與這些銷售相關的所有成本。因此,雖然對淨利沒有影響,但確實會讓營收端受到一些影響。如果我把這兩個因素調整回來,2% 的成長會更接近我們正常、預期的 4% 成長運行速度(run rate)。

  • - Analyst

    - Analyst

  • Great. And then maybe a quick follow-up on taking the team of top line. I guess one of the feedback we get from investors is -- look, companies, they've done a phenomenal job on the cost side, on the margins and the EPS growth. The end of this -- the products -- there's always -- it's hard to model a Company when you have so many SKUs. What gives you the confidence that Baxter could be 4% to 5%? When you look at the next two to three years, can you talk about when we can annualize some of the in-central [AST-bas] on some of the renal side, and some of these [growth in share] that's going to kick in? Thank you.

    很好。接著我想就營收端的團隊再快速追問一下。我想我們從投資人那邊收到的一個回饋是——你看,公司在成本端、在毛利率以及 EPS 成長方面做得非常出色。但在產品端——總是——當你有這麼多 SKU 時,要建模一家公司的確很難。是什麼讓你有信心 Baxter 可以達到 4% 到 5%?當你看未來兩到三年時,你能談談我們何時可以把腎臟業務那邊一些 in-central [AST-bas] 的效益年化,以及一些將會開始發酵的[市占成長]嗎?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Vijay, this is our challenge, and I think we on our on our way to create that environment. The first thing we did was completely reallocate capital. If I showed today to you the dollars invested by franchise in the Company versus 12 months ago, you'll see a significant difference. We are doubling down in areas like biosurgery. It's going to take us a couple of years to pick up momentum there because we fell behind in a lot of different things. But we are looking at some M&A augmentation for the short term.

    Vijay,這正是我們的挑戰,我認為我們正在打造那樣的環境。第一件事是我們已經徹底重新配置資本。如果我今天把公司按事業群投入的資金,拿來跟 12 個月前相比,你會看到非常顯著的差異。我們正在加碼像是生物外科(biosurgery)這些領域。那邊要花我們幾年時間才能重新累積動能,因為我們在很多不同面向都落後了。但短期內我們也在評估透過併購(M&A)來補強。

  • We also are doubling down in the PD business, the peritoneal dialysis business. I have great confidence that we are going to unveil a very different model of doing business in some parts of the world. We are working with payers at this moment, and I think there will be a very interesting way of extending the use of PD. Which has proven to be economically, and from the axis point of view, a better way forward for the patient and for the system. And with Sharesource, we are going to continue to invest there.

    我們也在加碼 PD 業務,也就是腹膜透析業務。我非常有信心,我們將在世界某些地區推出一個截然不同的營運模式。我們此刻正在與支付方合作,我認為會有一種非常有意思的方式來擴大 PD 的使用。這已被證明在經濟性上,以及從可近性(axis)角度來看,對病人與整個體系都是更好的前進方向。而在 Sharesource 方面,我們也會持續投資。

  • I see us very focused on the M&A area associated with organic growth in our generic injectable business. We think we have a platform opportunity at the moment. Plus, our internal growth engines, in terms of new molecules, which we're accelerating. So all of this gives me the confidence that we can achieve 4% to 5% in a couple of years.

    我看到我們會非常聚焦在與我們學名注射劑(generic injectable)業務的有機成長相關的併購領域。我們認為目前有一個平台型機會。此外,我們內部的成長引擎——就新分子而言——我們正在加速推進。所有這些都讓我有信心,我們可以在幾年內達到 4% 到 5%。

  • I tell you, we are trimming our portfolio. We are removing a significant amount of unprofitable dollars which will boost our 2017 bottom line. But cleaning up the portfolio and simplifying Baxter is also part of the playbook. So the playbook of innovation, really good capital allocation practices, use of capital dollars in a way that was different in the past. As you can see, our free cash flow numbers will allow us to generate more profitability for the Company.

    我跟你說,我們正在精簡產品組合。我們正在移除相當大一部分不具獲利性的營收,這將推升我們 2017 年的底線表現。但清理產品組合、簡化 Baxter 也是我們作戰手冊的一部分。所以,創新、非常好的資本配置做法、以不同於過去的方式運用資本資金,這些都是手冊內容。如你所見,我們的自由現金流數字將使我們能為公司創造更高的獲利能力。

  • And lastly, when we talk about transformation, it's not just cost reduction and reduction of personnel, but it's also the completely restructuring of the Company in terms of its processes. Baxter grew up to be a very complicated Company, with a lot of SKUs, and we're working very hard through the office of the business transformation to redo that. So that accumulation of factors give us pretty good odds of hitting the numbers. We just need to continue forth with a lot of tenacity to achieve what we set forth to do.

    最後,當我們談轉型時,不只是削減成本與裁減人員,也包括在流程面徹底重塑公司。Baxter 發展成一家非常複雜的公司,SKU 很多,而我們正透過業務轉型辦公室非常努力地重新梳理這些。因此,這些因素的累積讓我們有相當高的機率達成目標。我們只需要持續以很大的韌性往前推進,完成我們設定要做的事。

  • Operator

    Operator

  • Thank you. Our next question comes from Mike Weinstein, JPMorgan. Your line is now open.

    謝謝。下一個問題來自 JPMorgan 的 Mike Weinstein。您的線路已開通。

  • - Analyst

    - Analyst

  • Thank you. Good morning, and congrats, as well, on the quarter. Jay, I wanted to just clarify -- in the footnotes on some of the charges that were taken this quarter, it talks about $25 million of cost to implement business optimization programs, and that includes consultants and employee salaries. Just maybe walk through, why are those costs backed out of adjusted earnings?

    謝謝。早安,也恭喜本季表現。Jay,我想釐清一下——在本季認列的一些費用附註中,提到有 2,500 萬美元是用於執行業務最佳化計畫的成本,其中包含顧問費與員工薪資。能否請你說明一下,為什麼這些成本要從調整後盈餘中剔除?

  • - CFO

    - CFO

  • Look Mike, there are a couple of major programs, kind of one-time programs that we have ongoing which we don't expect to be permanent costs in place. And so for example, we have a -- what we call our Project Touchstone, which is related to the implementation of a global business service center. It really is not part of our ongoing operations. We do not have the expertise to do this ourselves, so we have brought in some consultants to assist in this process, and we have some employees dedicated to this process -- to the project, I should say.

    Mike,你看,我們目前有幾個主要計畫,算是一次性、我們正在進行中的計畫,我們不預期它們會成為永久性的成本。例如,我們有一個——我們稱之為 Project Touchstone——與建立全球商業服務中心的導入相關。它確實不是我們日常營運的一部分。我們沒有足夠的專業能力自行完成,所以我們請了一些顧問來協助這個流程,同時也有一些員工專職投入這個流程——更精確地說,是投入這個專案。

  • At some point, once implementation is complete, those costs will all go away, and they will benefit future periods, not current period. So that's just one example of a number of programs that we have in place which are not really a part of our ordinary operations, which we've chosen to special out.

    在某個時間點,當導入完成後,這些成本都會消失,而且它們帶來的效益會反映在未來期間,而不是當期。這只是我們目前所推動、且並非日常營運一部分的多個計畫中的一個例子,因此我們選擇將其單獨列示(special out)。

  • - Analyst

    - Analyst

  • Got you. Maybe next go to Joe on this. Joe, if I think about the pushback I hear from people, just going as the stories evolved here, it really revolves around just the idea that the success the Company is seeing is almost like a playbook of what we saw earlier from spec pharma companies. Where they took some otherwise mature, older products, raised some prices, and cut some costs, and that drove a rise in profitability in the short term. How do you evolve the story from being one of growth and earnings growth off of some price increases and cost-cutting at the front end, to one that is a more sustainable top- and bottom-line story?

    了解。接著也許把這題交給 Joe。Joe,如果我想想我從一些人那邊聽到的反對意見,隨著這個故事的演進,核心其實圍繞在這樣的想法:公司目前看到的成功,幾乎像是我們過去在某些專科藥廠(spec pharma)看到的作法——他們拿一些已成熟、較老的產品,提高價格、削減成本,短期內就推升了獲利。你要如何把故事從「靠前期漲價與成本削減帶動的成長與獲利成長」,演進成一個更可持續的營收與獲利(top- and bottom-line)故事?

  • - Chairman & CEO

    - Chairman & CEO

  • Mike, we don't have the portfolio [aspect] pharma Company, so our playbook is not quite the same. Do we have --

    Mike,我們並不是那種投資組合型的[專科]藥廠,所以我們的作戰手冊不太一樣。我們有——

  • - CFO

    - CFO

  • Joe, I think the comments are really focused on the price increases in the fluid systems and in the PD businesses.

    Joe,我想這些評論其實主要聚焦在輸液系統(fluid systems)以及 PD 業務的漲價。

  • - Chairman & CEO

    - Chairman & CEO

  • So I was going to add that our pricing today is slightly over 1.1% of our growth. So it's a fraction of the overall growth. Do we have price increases? We do have price increases, like many companies. But the sustainability -- what I see in the long-term is neutral to a slight positive on pricing. So I want to make that very clear.

    所以我想補充的是,我們目前的定價對成長的貢獻略高於 1.1%。也就是說,它只占整體成長的一小部分。我們有沒有漲價?我們確實有漲價,跟很多公司一樣。但就可持續性而言,我長期看到的是定價大致中性到略為正向。所以我想把這點講得非常清楚。

  • The other thing is, how do you sustain that top line, with transforming the gross margin contribution and participating in markets that have higher growth rates than our current one is, is using the playbook we are using today? So going into premixed and going into perhaps the manufacturing of very difficult-to-make APIs give us gross margins much different than we current today have, in terms of average for the Company. So we will double down on that. So Jay's comments in the very beginning about redeploying our R&D in the fourth quarter, is actually doubling down in other programs that we have in bringing new molecules to premix, using our capability of, we call, the galaxy.

    另外一點是,你要如何在轉型毛利貢獻、並參與成長率高於我們目前所處市場的市場時,去維持營收端?就是運用我們現在正在使用的作戰手冊。因此,切入預混(premixed),以及可能切入製造非常難製作的 API(原料藥),會讓我們的毛利率結構與我們目前公司的平均水準有很大不同。我們會在這些方面加碼。所以 Jay 一開始提到第四季重新部署我們的研發(R&D),其實就是在其他計畫上加碼,把新分子導入預混產品,運用我們所謂的 galaxy 能力。

  • Looking into adjacencies and doubling the amount of R&D in biosurgery is another sustainable way of being in this business. Creating local initiatives, that we are, and right now, we have more than probably 70 local initiatives in all countries. Remember, BAX is 60% outside-US sales. And we had put in place a franchise system, as a Company, that completely took away the ability of our local and regional businesses to operate a little bit more independent. And we have great opportunities that would total the significant amount of money in the next three to four years, that will sustain our top line, revamping our R&D organization to be more focused by business than focused in overall [cover].

    再者,尋找相鄰領域(adjacencies)並把生物外科的研發投入加倍,也是讓我們在這個產業中更可持續的一種方式。我們也在推動在地化倡議;目前在各國我們大概有超過 70 個在地倡議。記得,BAX 有 60% 的銷售在美國以外。而我們過去在公司內建立了一套事業群(franchise)制度,幾乎拿走了在地與區域業務更獨立運作的能力。我們現在有很好的機會,未來三到四年合計將帶來相當可觀的金額,支撐我們的營收端;同時也在重整研發組織,讓它更以業務為導向,而不是以整體[覆蓋]為導向。

  • So there's a significant amount of things we're doing that are not related directly to price, but eventually plays a role in pricing. Because your mix will be different if products have higher margins, and it will change the profile of the Company. It's not an easy thing to do, but we are working very hard to do it right. Hence, one of the things that we haven't rushed into doing was, acquiring companies. We want to make sure that we have the discipline to acquire the companies where it matters, and be strategically accretive to our business.

    所以我們正在做很多事情,並不是直接與價格相關,但最終會在定價上發揮作用。因為如果你的產品組合(mix)轉向更高毛利的產品,你的組合就會不同,也會改變公司的輪廓。這不是一件容易的事,但我們正非常努力把它做對。因此,我們一直沒有急著去做的一件事就是收購公司。我們要確保我們有紀律地在真正重要的地方收購,並在策略上對我們的業務具增益性(accretive)。

  • - Analyst

    - Analyst

  • Understood. Thanks, Joe.

    了解。謝謝你,Joe。

  • Operator

    Operator

  • Thank you. And our next question comes from Bob Hopkins of Bank of America. Your line is now open.

    謝謝。下一個問題來自美國銀行(Bank of America)的 Bob Hopkins。您的線路已開通。

  • - Analyst

    - Analyst

  • Hi, thank you very much. Can you hear me okay?

    嗨,非常感謝。你們聽得到我說話嗎?

  • - VP of IR

    - VP of IR

  • Yes, we can, Bob.

    是的,我們聽得到,Bob。

  • - Analyst

    - Analyst

  • Great. Congratulations on the great margin performance. So I wanted to focus my questions on the margin performance. And Joe, maybe I will start with you, and then a question for Jay, to follow up. So Joe, I was just wondering if you could kind of characterize the out-performance on margins from a big picture perspective? What I'm curious about is, how much of this out-performance is basically pull-forward of margin opportunities that you anticipated in the long-range plan, versus finding new areas of savings that were not originally anticipated in the LRP? So I'm just kind of curious how much of this is pull-forward versus finding new opportunities?

    很好。恭喜你們在毛利率表現上做得非常出色。所以我想把問題聚焦在毛利率表現上。Joe,我可能先從你開始,接著再問 Jay 一個追問。Joe,我想請你從宏觀角度描述一下毛利率超預期的表現?我好奇的是,這些超預期表現中,有多少基本上是把你們在長期計畫(LRP)中原本預期的毛利率改善機會提前實現(pull-forward),又有多少是找到原先在 LRP 中未預期到的新節省領域?所以我想了解,這當中有多少是提前實現、多少是找到新機會?

  • - Chairman & CEO

    - Chairman & CEO

  • Well, Bob, you answered 50% of my question -- of your own question. We've got accelerated programs in place, and we are getting faster results on our zero-based organizations, zero-based budget and zero-based spending. So we pulled things forward. But we also have come across a significant amount of opportunities that we initially did not anticipate. So I see us building a lot of confidence, and probably over-achieving our targets. And I say that with no hesitation.

    嗯,Bob,你已經回答了我問題的 50%——也就是你自己問題的一半。我們已經啟動加速方案,而且在零基組織、零基預算與零基支出方面,我們取得成果的速度更快。所以我們確實把一些事情提前了。但同時,我們也發現了相當多一開始並未預期到的機會。因此我看到我們的信心正在大幅提升,而且很可能會超額達成我們的目標。我毫不猶豫地這麼說。

  • I would say also that there is a portion of our restructuring that is more complex, which is the outsourcing and labor arbitration that is involved in changing our back-office profile. But based on what I did in the past and looking at what we are doing today, there is a vast difference in our approach. And I truly believe that our people will be able to do what we set forth to do, at the savings that we set or even better. So things are coming together very well.

    我也會說,我們重整中有一部分更為複雜,也就是為了改變我們後勤(back-office)配置所涉及的外包與勞資仲裁。但根據我過去的經驗,以及對比我們今天正在做的事情,我們的方法有很大的不同。我真心相信,我們的團隊能夠完成我們所設定要做的事,並以我們設定的節省金額達成,甚至更好。所以整體進展非常順利。

  • One thing I want to give credit to Baxter and the Baxter management and Baxter employees, is, once we set our compass to the right direction here, they really execute very quickly. I was surprised how much momentum we got out of simplification and savings. The folks of our Company have done a phenomenal job embracing these changes, and those are not easy changes to make. So in summary, we are happy with the results -- and satisfied, by the way. And it just give us confidence that probably we will over-achieve on our long-range plan targets.

    我想要肯定 Baxter、Baxter 的管理團隊以及 Baxter 的員工:一旦我們把方向盤轉到正確的方向,他們的執行速度真的非常快。我對於簡化與節省所帶來的動能之大感到驚訝。我們公司的同仁在擁抱這些變革方面做得非常出色,而這些變革並不容易推動。總結來說,我們對結果感到高興——順帶一提,也感到滿意。這也讓我們更有信心,長期計畫的目標很可能會超額達成。

  • - Analyst

    - Analyst

  • Thank you for that. I appreciate that. And then, Jay, a little more short-term oriented question around the fourth-quarter guidance. You characterize the fourth-quarter margin guidance as a slight downtick from Q3, but unless I'm doing my math wrong, it looks like operating margins will come down 200 to 300 basis points in Q4 versus Q3. So I guess I'm just curious. One, do I have my math right?

    謝謝你的說明,我很感激。接著,Jay,我有一個比較偏短期、關於第四季指引的問題。你把第四季的毛利率指引描述為相較 Q3 略為下滑,但除非我算錯了,看起來第四季的營業利益率會比 Q3 下降 200 到 300 個基點。所以我想確認一下:第一,我的計算對嗎?

  • And two, were there any one-timers in Q3 in that 16%, or is that a clean number? And then maybe you could just talk a little bit more about the increase in spending in R&D from Q3 to Q4? Thank you.

    第二,Q3 的 16% 裡面有沒有任何一次性因素(one-timers),還是這是一個乾淨的數字?另外,你能否再多談一點,為什麼從 Q3 到 Q4 研發(R&D)支出會增加?謝謝。

  • - CFO

    - CFO

  • I mean, look, 16% -- great quarter. We were really happy with it. The full year we expect to be around 13%. And so while there weren't one-timers in place, we do expect to see a, what I call, downtick, you call 200 to 300 basis points of deterioration in the fourth quarter -- which I think is fair.

    我的意思是,你看,16%——這是一個很棒的季度。我們對此非常滿意。全年我們預期大約在 13% 左右。因此,雖然並沒有一次性因素,但我們確實預期第四季會出現我所說的「小幅下滑」——你稱之為惡化 200 到 300 個基點——我認為這樣的說法是合理的。

  • And as I said, there's a couple of factors, right? It's probably split roughly evenly between R&D and SG&A. From an R&D standpoint, one of the areas we really want to accelerate and we recognize investments today will yield dividends in a couple of years, relates to biosurgery. So we started to accelerate spending there. There were a number of programs that will begin in earnest in the fourth quarter that will facilitate that.

    如我所說,這裡有幾個因素,對吧?大概在研發與銷售、一般及行政費用(SG&A)之間各占一半。就研發而言,我們非常想加速、而且也認知到今天的投資會在兩年後帶來回報的其中一個領域,是生物外科(biosurgery)。所以我們開始加速那裡的支出。有一些專案會在第四季正式啟動,以推動這件事。

  • And then to Joe's comment earlier, this point of care, another very exciting development for us. It's got a lot of benefits for the patients. It's a great program for us. It also allows us to run a capital-light model relative to the historic way of delivering PD solutions to patients. So very exciting developments, but they have a cost associated with them. We do expect to see that impact on margin by 1 point roughly, and then SG&A is maybe a little bit more than that. For us, Q3 was a low level of SG&A spending. The Q4 number, we are expecting to move back up to roughly the Q2 level. We would historically expect to see a Q4 uptick. Q3 is typically a lower SG&A spend quarter -- in part, because of the August month, which is a holiday in many parts of the world. So for us, we are being prudent and thinking about an uptick in spending to occur in the fourth quarter.

    另外呼應 Joe 先前的評論,這個照護現場(point of care)也是我們非常令人振奮的另一項發展。它對病患有很多好處,對我們而言也是很棒的計畫;相較於過去向病患提供腹膜透析(PD)解決方案的歷史方式,它也讓我們能採用較輕資本(capital-light)的模式。所以這些都是非常令人興奮的進展,但也伴隨成本。我們預期對毛利率的影響大約是 1 個百分點,而 SG&A 可能略高於此。對我們來說,Q3 的 SG&A 支出水準偏低;Q4 我們預期會回升到大約 Q2 的水準。歷史上我們通常會看到 Q4 的支出上升。Q3 通常是 SG&A 支出較低的季度——部分原因是 8 月在世界許多地方是休假月份。因此,我們採取審慎態度,預期第四季會出現支出上升。

  • But then to the last point, we've got to accelerate to top line, that is a clear charge of our entire Company, and that takes some investment as well. We have empowered our international organization to begin spending on a number of initiatives. There's no impact on the sales line related to these, of note, in 2016, but these investments will start to pay dividends and self-fund in 2017 and 2018. So very exciting development there. Good investments to make. We track and monitor these investments on a monthly and quarterly basis.

    但再談最後一點,我們必須加速營收成長(top line),這是我們整個公司的明確任務,而這也需要一些投資。我們已授權國際組織開始在多項倡議上投入支出。這些在 2016 年對銷售額(sales line)沒有值得一提的影響,但這些投資會在 2017 與 2018 年開始帶來回報並自我挹注(self-fund)。所以那也是非常令人振奮的發展,是值得做的投資。我們會以每月與每季的頻率追蹤並監控這些投資。

  • But in combination, these elements lead to a slight deterioration from the 16% level. Having said all of that, to Joe's point, we shared some projections in May of 2016. For margin in 2018, we said, 14% to 15%. In 2020, we said, 17% to 18%. We have a higher likelihood of over-achieving those numbers as we sit here today. That's clear.

    但綜合而言,這些因素會導致相較 16% 水準略有惡化。話雖如此,回到 Joe 的觀點,我們在 2016 年 5 月分享過一些預測:2018 年的毛利率我們說是 14% 到 15%;2020 年我們說是 17% 到 18%。以我們目前所見,我們更有可能超越這些數字。這點很明確。

  • - Analyst

    - Analyst

  • Very helpful. Thanks guys.

    非常有幫助。謝謝各位。

  • Operator

    Operator

  • Thank you. And our next question comes from Brooks West of Piper Jaffray. Your line is now open.

    謝謝。下一個問題來自 Piper Jaffray 的 Brooks West。您的線路已開通。

  • - Analyst

    - Analyst

  • Hi, thanks. Can you hear me?

    嗨,謝謝。你們聽得到我嗎?

  • - CFO

    - CFO

  • Yes. Hi, Brooks.

    是的。嗨,Brooks。

  • - Analyst

    - Analyst

  • Great. Good morning. I had a question. I'm trying to tease out organic growth opportunities, more on the Hospital Products side of the business. And I'm specifically looking at the difference in performance between the US and international businesses. So Jay, I wonder, do you have a sense for the underlying growth rate if you back out either the product lines or the geographies that you are exiting in that business?

    很好。早安。我有個問題。我想釐清一些內生成長(organic growth)機會,主要是在醫院產品(Hospital Products)這一端的業務。我特別在看美國與國際業務之間表現的差異。Jay,我想請問,你是否能估算一下:如果把你們在該業務中正在退出的產品線或地理區域排除掉,底層的成長率大概會是多少?

  • And then secondly, if you look at organic growth opportunities within Hospital Products, can you talk about even just getting the entire portfolio approved in all geographies? Can you help us understand kind of the organic growth opportunity within -- and I guess I'm thinking more injectables and nutrition? That's question number one.

    第二,如果看醫院產品內的內生成長機會,你能否談談例如讓整個產品組合在所有地區都取得核准?能否幫我們理解一下在——我想我主要指的是注射劑(injectables)與營養(nutrition)——這些領域中的內生成長機會?這是第一個問題。

  • - CFO

    - CFO

  • Yes, sure. Look, the overall hospital -- as far as the exits that took place, it actually was slightly tilted towards renal. So we looked at the India-India business. We made some decisions related to IVs in PD. In Turkey, we looked at our clinics business, along with the IV business there. But on balance, I would say, slightly more of an impact in renal than it was in the hospital business.

    是的,當然。你看,整體醫院——就已發生的退出而言,其實稍微偏向腎臟(renal)業務。我們檢視了印度的業務。我們也針對 PD 的靜脈輸液(IVs)做了一些決策。在土耳其,我們檢視了診所(clinics)業務,以及那裡的 IV 業務。但整體而言,我會說對腎臟業務的影響略大於對醫院業務的影響。

  • To be clear, we've had outstanding performance in the US hospital business, right? The 6% growth has been quite good. And internationally, the growth is below that. And so you ask a great question, which is -- how do we accelerate growth outside the US?

    說清楚一點,我們在美國的醫院業務表現非常出色,對吧?6% 的成長相當不錯。而在國際市場,成長低於這個水準。所以你問了一個很好的問題,也就是——我們要如何在美國以外加速成長?

  • The US has benefited from a number of factors which are not quite present internationally. We've had the benefit of a new product launch, the Sigma Spectrum pump. We've had very solid performance coming from our nutrition business, and we've seen adequate performance coming out of our surgical care business. But the real standout performance comes from the US fluid systems business. Outside the US, we have not had the benefit of a product launch like we've had in the US.

    美國受惠於一些在國際市場並不完全具備的因素。我們受惠於新產品上市,也就是 Sigma Spectrum 幫浦。我們的營養業務表現非常穩健,而外科照護(surgical care)業務也有尚可的表現。但真正突出的表現來自美國的輸液系統(fluid systems)業務。在美國以外,我們並沒有像在美國那樣受惠於產品上市。

  • And so for us, how do we address the new products perhaps from a business development standpoint, outside the US? For example, in the fluid systems business, that's a real challenge and opportunity for us as we look to accelerate performance outside the US.

    因此,對我們而言,從業務發展的角度來看,我們要如何在美國以外應對這些新產品?例如,在流體系統業務方面,當我們希望加速美國以外的表現時,這對我們來說既是重大挑戰,也是重大機會。

  • In addition, our nutrition business, which, in the quarter in the United States, grew in double-digits, grew in low single-digits outside the US. And so for us, another real area of focus has been accelerating the nutrition performance outside the US. And that will continue to be an area where we will invest. Some of the investment initiatives are targeting nutrition growth outside the US.

    此外,我們的營養業務在本季於美國實現了兩位數成長,但在美國以外僅呈現低個位數成長。因此,對我們而言,另一個真正的重點領域是加速美國以外的營養業務表現。而這也將持續是我們會投入資源的領域。我們的一些投資計畫正是以推動美國以外的營養成長為目標。

  • So those are a few of the factors. It's kind of a difficult question to answer, in the sense that it really is multi-product, multi-geography. But it's safe to say that accelerating performance -- renal outside the US has seen outstanding performance, 5% for the quarter. That was a very solid performance for us. Accelerating the hospital outside the United States becomes a core area of focus for us, in particular as we move to 2017.

    所以,以上是其中幾個因素。這個問題有點難回答,因為它確實牽涉到多產品、多地區。不過可以肯定的是,要加速表現——腎臟業務在美國以外本季表現非常出色,季度成長5%。這對我們來說是非常穩健的表現。加速美國以外的醫院業務將成為我們的核心重點領域,特別是在我們邁向2017年之際。

  • - Analyst

    - Analyst

  • That's helpful. And then I guess as a follow-up, you talked about M&A, but really haven't pulled the trigger on anything yet. And I know Joe mentioned earlier, some of that is internal timing. But can you talk about the barriers that you see to doing M&A? I mean, is it scarcity of assets, is it pricing? What's the opportunity, and what's really holding you back from pulling the trigger? Thanks.

    這很有幫助。接著我想追問一下,你談到了併購(M&A),但似乎還沒有真正對任何案子扣下扳機。我也知道 Joe 先前提到,其中一部分是內部時程的因素。但你能談談你認為進行併購的障礙是什麼嗎?我的意思是,是標的稀缺、還是價格因素?機會在哪裡?又是什麼真正讓你們遲遲沒有扣下扳機?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • We have targets that are probably in the number of between 10 and 15, that we have in front of us at any given time. So it's not a scarcity of targets. And now we have a strategy that is driving our seeking companies and seeking businesses and technology. So now we have the right construct here, which it's strategy driving M&A.

    我們在任何特定時間點,眼前大概都有10到15個目標。因此並不是缺乏標的。現在我們也有一套策略在驅動我們去尋找公司、尋找業務與技術。所以我們現在有了正確的架構,也就是由策略來驅動併購。

  • We are extremely disciplined when it comes to how we look at our shareholders' money. And the ability to drive value is fundamentally important to us. So at the moment, we are looking at three specific targets that we think have good value for the Company. The competition sometimes is irrational about how people are paying for some of the targets, and we don't go there. We don't want to be part of that group. We want to make sure that everything that we pay for has a way of paying back to the Company and to the shareholders.

    在如何看待股東的資金方面,我們極其自律。而能否創造價值對我們而言是根本性的重點。因此目前我們正在評估三個特定標的,我們認為它們對公司具有良好價值。有時競爭對手在支付某些標的價格時並不理性,而我們不會走那條路。我們不想成為那一群的一部分。我們要確保我們所支付的每一分錢,都有辦法回饋公司與股東。

  • So we are very diligent. I meet with the team every month. Every other week I get updates. We just hired our new head of M&A. He started with us about a week and a half ago. Very talented. I want our investors to understand that we are very focused on that, but we will never forget our responsibility in managing our shareholders' money. We don't see it as our money; it's our shareholders'. So we're going to make sure that investments that we make are very well-thought-out. I also challenged our team internally to think a little broader when we take a look at acquisitions, and make sure that we understand all the values being captured.

    所以我們非常審慎。我每個月都會與團隊開會;每隔一週我就會收到更新。我們剛聘請了新的併購主管,他大約在一週半前加入我們,非常有才華。我希望投資人了解,我們對此非常專注,但我們永遠不會忘記管理股東資金的責任。我們不把它視為我們的錢;那是股東的錢。因此我們會確保所做的投資都經過周全思考。我也在內部挑戰團隊,在檢視收購案時要想得更廣一些,並確保我們理解所有被捕捉到的價值。

  • So this has been a learning curve for Baxter. We have not done that in the past, and I think it's a good practice. So as we get more mature, we are probably going to see some things happening in the future.

    因此,這對 Baxter 來說是一段學習曲線。我們過去沒有這樣做過,而我認為這是一個好的做法。隨著我們更加成熟,未來我們可能會看到一些事情發生。

  • - Analyst

    - Analyst

  • That's helpful. Thanks, guys.

    這很有幫助。謝謝各位。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. And our final question comes from the line of Larry Beigelsen of Wells Fargo. Your line is now open.

    謝謝。接下來我們的最後一個問題來自 Wells Fargo 的 Larry Beigelsen。您的線路已開通。

  • - Analyst

    - Analyst

  • Good morning, thanks for taking the question. Joe, I heard the comment earlier about getting to 4% to 5% growth in a couple years, but I just wanted to focus first on 2017. Can you talk about some of the headwinds and tailwinds investors should think about?

    早安,謝謝讓我提問。Joe,我先前聽到你提到在幾年內達到4%到5%的成長,但我想先聚焦在2017年。你能談談投資人應該考量的一些逆風與順風因素嗎?

  • We estimate that cyclo, in exiting low-margin sales, could be about a 200-basis point headwind next year. Are we in the right ballpark? And the 2016 to 2018 sales CAGR you provided at the May investor meeting was 3% to 4%, I believe. Is there any reason why you can't do 3% to 4% in 2017? I did have one follow-up. Thanks.

    我們估計 cyclo 透過退出低毛利銷售,明年可能會帶來約200個基點的逆風。我們的估計是否大致正確?另外,你在5月投資人會議上提供的2016到2018年銷售CAGR我記得是3%到4%。有任何原因讓你們在2017年無法做到3%到4%嗎?我還有一個追問。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • We're not going to talk about 2017 today. What I want to tell you is that we will remove sales from the top line which are unprofitable today. And that is our responsibility. So we do have the long-term objective of growing the business, and the underlying business will grow 3% to 4%. The thing is, we will need to remove some sales we have.

    我們今天不會談2017年。我想告訴你的是,我們會把目前不具獲利性的銷售從營收端移除。這是我們的責任。因此我們確實有長期目標要成長業務,而基礎業務將成長3%到4%。問題在於,我們需要移除一部分現有的銷售。

  • We're doing business in locations that we should not be doing business. We've been there for a long time, but it has not panned out to be a good business. And the worst thing that we can have is to keep a business afloat that is, on the marginal contribution, is eroding value to the Company. So we will take the matters that we want to take, and make sure that anything that we do will have the intentions of making the Company stronger in the future.

    我們在一些不該經營的地點做生意。我們在那裡已經很久了,但結果並沒有成為一門好生意。我們最糟糕的情況,就是讓一個在邊際貢獻上正在侵蝕公司價值的業務繼續苟延殘喘。因此我們會採取我們想採取的措施,並確保我們所做的任何事情,都是為了讓公司在未來更強大。

  • So for us, if we deliver our bottom line, we will have to take some of this business offline, and I have no problems with that. At the same time, we are very focused on investing in the right R&D programs, to be able to create the momentum to bring the top line to the 3% to 4%; eventually, 4% to 5%. This is our job. Number one right now is to work on top-line growth. But we will revamp and re-purpose our portfolio, so we're not here sitting three, four years from today with massive unwanted businesses that we should have taken action before.

    所以對我們而言,如果要交付我們的獲利表現,我們就必須讓其中一些業務下線,我對此完全沒有問題。同時,我們也非常專注於投資正確的研發(R&D)計畫,以創造動能,讓營收端回到3%到4%,最終達到4%到5%。這就是我們的工作。當下第一要務是推動營收成長。但我們也會重整並重新定位我們的產品組合,避免三、四年後我們還坐在這裡,面對大量不想要的業務,而那些其實早就應該採取行動。

  • - Analyst

    - Analyst

  • Very clear. Joe, just a follow-up on capital allocation. You've talked about bringing your net debt-to-EBITDA level to about 2 times in the next couple of years. Is there any timeline when you expect to be at 2 times? And how do you strike the balance between waiting for the right deal to come along versus returning cash to shareholders via share repurchases? Thanks for taking the questions.

    非常清楚。Joe,我想就資本配置再追問一下。你提到在接下來幾年把淨負債對EBITDA的水準降到約2倍。你預期何時會到2倍?另外,在等待合適交易出現與透過庫藏股回購把現金回饋給股東之間,你們如何取得平衡?謝謝讓我提問。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you. We are very happy with our progress on free cash flow. And we see, with better management of our capital, we'll see probably a better performance that we have spoken to our investors back in May. With that said, it gives us a good ability to deploy this capital in acquisitions. So we will have not a timeline fixed to get to a 2.0; we will get there when we get there. And it can be in one shot, it can be in several shots.

    謝謝。我們對自由現金流的進展非常滿意。我們也看到,透過更好的資本管理,我們的表現可能會優於我們在5月向投資人所談到的水準。話雖如此,這也讓我們有很好的能力把這些資本部署到收購上。因此,我們不會設定一個固定的時間表一定要達到2.0;我們會在達到時就達到。可能一次到位,也可能分幾次完成。

  • But we are really focused in bringing our balance sheet to a place that we can either do two things -- choose to deliver capital to our shareholders in the form of buyback, and I think that is a very possible avenue, combined with a healthy M&A strategy. Because we are very happy with how our free cash flow and our capital spending is progressing.

    但我們確實非常專注於把資產負債表調整到一個位置,使我們可以做兩件事——選擇以回購的形式把資本回饋給股東,我認為這是非常可行的一條路徑,同時搭配健康的併購策略。因為我們對自由現金流與資本支出的進展非常滿意。

  • - Analyst

    - Analyst

  • Thanks for taking the questions.

    謝謝讓我提問。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference with Baxter International. Thank you for your participation, and have a great day.

    各位女士、先生,今天 Baxter International 的電話會議到此結束。感謝各位的參與,祝各位有美好的一天。